share Special Report: Creso Pharma’s first medical cannabis product has landed in Australia as the company sets itself up for 2020 as a truly global player in the industry. Creso Pharma’s (ASX:CPH) first shipment of its flagship medicinal cannabis product cannaQIX® 50 has arrived in Australia and is already being sold. The medicinal cannabis product, sold under the brand name ‘LozaCan’ via Burleigh Heads Cannabis’ distribution network, is already being prescribed and is receiving positive feedback from physicians and patients. Creso Pharma and Burleigh Heads Cannabis are now exploring the potential to expand their collaboration to include more products from Creso Pharma’s pipeline into the Australian market. “We are pleased to announce the first delivery of cannaQIX® 50 in Australia. Burleigh Heads Cannabis and CDA Clinics Australia continue to rapidly expand their patient reach with their extensive distribution network,” Creso CEO and cofounder Dr Miri Halperin Wernli said. “This […]